Prof. Dr. Frank Bradke
German Center for Neurodegenerative Diseases (DZNE)
frank.bradke@dzne.de View member: Prof. Dr. Frank Bradke
EMBO molecular medicine
The recent years saw the advent of promising preclinical strategies that combat the devastating effects of a spinal cord injury (SCI) that are progressing towards clinical trials. However, individually, these treatments produce only modest levels of recovery in animal models of SCI that could hamper their implementation into therapeutic strategies in spinal cord injured humans. Combinational strategies have demonstrated greater beneficial outcomes than their individual components alone by addressing multiple aspects of SCI pathology. Clinical trial designs in the future will eventually also need to align with this notion. The scenario will become increasingly complex as this happens and conversations between basic researchers and clinicians are required to ensure accurate study designs and functional readouts.
© 2020 The Authors. Published under the terms of the CC BY 4.0 license.
PMID: 32090481
German Center for Neurodegenerative Diseases (DZNE)
frank.bradke@dzne.de View member: Prof. Dr. Frank Bradke